-
INITIATION WITH GLP-1 RECEPTOR AGONISTS TREATMENT FOR OBESITY IN PATIENTS WITH MENTAL HEALTH CONDITIONS - A REAL WORLD DATA RETROSPECTIVE STUDY
Feb 25, 2026, 14:41 PM -
SLEEP DISORDER DIAGNOSIS IN ADOLESCENCE AND SUBSEQUENT MENTAL HEALTH DIAGNOSES - A RETROSPECTIVE COHORT STUDY
Feb 25, 2026, 14:41 PM -
AFFORDABILITY OF PEDIATRIC DRUGS THROUGH CHINA’S NATIONAL DRUG PRICE NEGOTIATION: 2017-2024
Feb 25, 2026, 14:41 PM -
MULTILEVEL SOCIOECONOMIC AND REGIONAL DISPARITIES IN MATERNAL HEALTHCARE ACCESS IN A HIGH-BURDEN SETTING
Feb 25, 2026, 14:41 PM -
MEAN OVERALL SURVIVAL FROM THE PHASE 3 MIRASOL TRIAL OF MIRVETUXIMAB SORAVTANSINE VS INVESTIGATOR’S CHOICE OF CHEMOTHERAPY IN WOMEN WITH FR?-HIGH PLATINUM-RESISTANT OVARIAN CANCER (GOG 3045/ENGOT-OV55; NCT04209855)
Feb 25, 2026, 14:41 PM -
MAPPING PATIENT-REPORTED OUTCOMES EVIDENCE REQUIREMENTS ACROSS GLOBAL MARKETS
Feb 25, 2026, 14:41 PM -
UNDERSTANDING CEA CHARACTERISTICS ASSOCIATED WITH COST-SAVING FINDINGS
Feb 25, 2026, 14:41 PM -
A REAL-WORLD EVIDENCE STUDY OF EPIGENOMIC SUBTYPING IN LIQUID BIOPSY-BASED LUNG CANCER COHORTS
Feb 25, 2026, 14:41 PM -
REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS OF RHEUMATOID ARTHRITIS IN DUBAI: A CLAIMS-BASED ANALYSIS
Feb 25, 2026, 14:41 PM -
FEASIBILITY OF INDIRECT TREATMENT COMPARISONS FOR OAV101 IT IN SPINAL MUSCULAR ATROPHY
Feb 25, 2026, 14:41 PM -
DEVELOPMENT AND VALIDATION OF AN ALGORITHM TO IDENTIFY ASPIRIN USE FROM ELECTRONIC MEDICAL RECORDS AND CLAIMS DATA
Feb 25, 2026, 14:41 PM -
APPLYING TARGET TRIAL EMULATION IN VACCINE RESEARCH: METHODOLOGICAL INSIGHTS AND REGULATORY IMPLICATIONS
Feb 25, 2026, 14:41 PM -
BUDGET IMPACT ANALYSIS OF EXAGAMGLOGENE AUTOTEMCEL FOR PATIENTS WITH SICKLE CELL DISEASE AND RECURRENT VASO-OCCLUSIVE EVENTS IN THE UNITED STATES
Feb 25, 2026, 14:41 PM -
PREDICTORS OF INITIATING MEDICATIONS FOR OPIOID USE DISORDER IN THE EMERGENCY DEPARTMENT: A RETROSPECTIVE COHORT STUDY
Feb 25, 2026, 14:41 PM -
USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS
Feb 25, 2026, 14:41 PM -
INCORPORATING REAL OPTION VALUE IN THE ECONOMIC EVALUATION OF OSIMERTINIB FOR ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Feb 25, 2026, 14:41 PM -
REIMBURSEMENT VARIABILITY FOR MULTIPLE MYELOMA HOSPITALIZATIONS IN BRAZIL: EVIDENCE FROM THE NATIONAL SUPPLEMENTARY HEALTH AGENCY DATABASE AS A DISEASE-SPECIFIC COST SOURCE
Feb 25, 2026, 14:41 PM -
ECONOMIC BURDEN ASSOCIATED WITH SJÖGREN’S DISEASE (SJD): A SYSTEMATIC LITERATURE REVIEW (SLR)
Feb 25, 2026, 14:41 PM -
ECONOMIC EVALUATION OF BLINATUMOMAB PLUS CHEMOTHERAPY IN CHILDREN WITH STANDARD RISK B CELL ACUTE LYMPHOBLASTIC LEUKEMIA AT AVERAGE RISK OF RELAPSE IN HONG KONG
Feb 25, 2026, 14:41 PM -
COST EFFECTIVENESS ANALYSIS OF SONPIRETIGENE ISTEPARVOVEC FOR RETINITIS PIGMENTOSA WITH SEVERE VISION LOSS
Feb 25, 2026, 14:41 PM
